Omadacycline

Drug Profile

Omadacycline

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; PTK-0796; PTK796

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; Skin and soft tissue infections
  • Phase I Nosocomial infections; Urinary tract infections
  • Preclinical Acute sinusitis; Respiratory tract infections
  • Research Anthrax; Plague

Most Recent Events

  • 03 Jun 2017 Preclinical trials in Respiratory tract infections in USA (unspecified route)
  • 03 Jun 2017 Pharmacodynamics data from a preclinical trial in Acute skin and skin structure infections, Respiratory tract infections and Urinary tract infections released by Paratek Pharmaceuticals
  • 08 May 2017 Paratek Pharmaceuticals completes enrolment in its phase III trial for Skin and soft-tissue infections in USA (PO) (NCT02877927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top